The Lancet highlights Parc researchers' commitment to integrating psychedelics with psychotherapy

Psychedelic treatment is gaining momentum in Europe, and a Lancet publication highlights Parc researchers pushing for psychotherapy integration rather than medication alone. The article, co-authored by psychiatrist Oscar Soto-Angona and psychologist Genís Oña from the Ànima group, discusses evidence from clinical trials suggesting psychedelics could help patients with depression, PTSD, anxiety, and existential distress when paired with therapy. It also flags an unresolved question about how long these effects persist. The authors emphasize that psychedelic care depends on the interaction between neurobiological effects and psychological, relational, and environmental context. They argue that regulation is a central challenge and point to emerging regulatory pathways in Europe, including limited medical use programs and compassionate use approvals involving specific substances.